FLAVIOLA Health Study
- Conditions
- Vascular Health
- Interventions
- Dietary Supplement: Flavanol (410 mg)Dietary Supplement: Control (no flavanols)
- Registration Number
- NCT01799005
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
Atherosclerosis progressively occurs with increasing age in the general population. So far most dietary intervention studies with flavanols were performed over short time frames and in small groups of young healthy and older patients with manifest cardiovascular disease, respectively. Vascular health is defined as absence of vascular disease and the presence of optimal parameters that determine the development and progression of arteriosclerosis (endothelial function, blood pressure, plasma lipids, and glucose). It is not clear whether flavanols can improve parameters of vascular health, most importantly endothelial function, when given repetitively to healthy middle aged and which factors affect the efficacy of flavanol interventions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
- male, age 35-60 years, healthy
- female, age 35-60 years, healthy
- diabetes mellitus, acute inflammation, arrhythmia, active malignancy, terminal renal failure, signs, symptoms or medication indicative of manifest cardiovascular disease (CAD, PAD, CVD)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description flavanol rich intervention Flavanol (410 mg) Ingestion of 410mg flavanols twice a day for 30 days flavanol free intervention Control (no flavanols) Ingestion of a macro and micro nutrients matched flavanol free drink
- Primary Outcome Measures
Name Time Method Endothelial function Time points: day 0 [baseline], and day 30 each 0 and 2h.
- Secondary Outcome Measures
Name Time Method Blood pressure Time points: day 0 [baseline], and day 30 each 0 and 2h. Glucose Time points: day 0 [baseline], and day 30 each 0 and 2h. Plasma lipids Time points: day 0 [baseline], and day 30 each 0 and 2h.
Trial Locations
- Locations (1)
Division of Cardiology, Pulmonology and Vascular Medicine
🇩🇪Duesseldorf, NRW, Germany